Obesity
Conditions
Brief summary
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
Detailed description
This study will assess the safety, tolerability and weight loss associated with XEN-101 in obese men and women.
Interventions
DRUGXEN-101
capsule formulation
DRUGPlacebo
capsule formulation
Sponsors
Xeno Biosciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, age 18 to 60 years, inclusive, at Screening 2. Body mass index of 30 to 45 kg/m2 3. Stable body weight for at least 3 months (i.e., fluctuation of ≤5%) 4. If a female of childbearing potential, must agree to use double barrier contraception (e.g., condom and 1 additional form of adequate contraception) from the date of signing of the ICF, throughout the study, and for 4 weeks after the final dose of study drug. In addition, she must be advised not to donate ova during this period. If a non-sterilized male is sexually active with a female partner of childbearing potential, he must use double barrier contraception from the date of signing of the ICF, throughout the study, and for 8 weeks after the final dose of study drug. In addition, he must be advised not to donate sperm during this period 5. If a female of childbearing potential, must have a negative pregnancy test at Screening and on Day 1 (baseline) 6. Able to provide informed consent 7. Willing and able to comply with this protocol and procedures, including feces collection, and be available for the entire duration of the study
Exclusion criteria
1. Currently enrolled in another investigational device or drug study, or less than 30 days or 5 times the half-life of the drug candidate (whichever is longer) has passed between Screening for this study and the end of the Treatment Period of the previous investigational device or drug study 2. Diagnosed with type 1 diabetes or type 2 diabetes (T2D) (resolution of T2D \>3 years before Screening is allowed) 3. Laboratory evidence during Screening of T2D, including glycated hemoglobin (HbA1c) ≥6.5% or fasting glucose ≥126 mg/dL (≥7.0 mmol/L) 4. Evidence of clinically significant cardiac, neurologic, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the Investigator's opinion, would compromise the safety of the subject, interfere with the interpretation of the study results, or otherwise preclude subject participation 5. Female who is pregnant, nursing, or intends to become pregnant during the study. 6. Positive result for hepatitis B virus surface antigen, hepatitis C virus ribonucleic acid, and human immunodeficiency virus (HIV) antibody at Screening 7. Use of anti-obesity medications (e.g., glucagon-like peptide-1 analogues, stimulants, bupropion/naltrexone) within 6 months before Screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment emergent adverse events (safety and tolerability) | Day 1 through Day 43 | Assessing the type and frequency of adverse events |
| Effect on body weight | Day 1 through Day 43 | change and percent change from baseline |
Countries
Australia
Outcome results
None listed